A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic NSCLC - ARTEMIDE-01

Study identifier:D7020C00001

ClinicalTrials.gov identifier:NCT04995523

EudraCT identifier:2021-000857-23

CTIS identifier:N/A

Recruitment Complete

Official Title

Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic NSCLC

Medical condition

Non-Small-Cell Lung Carcinoma

Phase

Phase 1/2

Healthy volunteers

No

Study drug

AZD2936

Sex

All

Actual Enrollment

179

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 14 Sept 2021
Estimated Primary Completion Date: 20 Apr 2026
Estimated Study Completion Date: 20 Apr 2026

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria